This Scientist Stands To Make Billions With Custom Gene-Editing Tools

Benjamin Oakes' Scribe Therapeutics is developing specialized Crispr proteins for multiple diseases–and it’s got deals with Big Pharma potentially worth over $4 billion

Related Keywords

United States ,California ,Berkeley ,Brett Staahl ,Johns Hopkin Modell ,Kazi Helal ,Joshua Modell ,Behzad Aghazadeh ,Greg Yap ,Deanonymize Blockchain ,Benjamin Oakes ,Andreessen Horowitz ,Jennifer Doudna ,Johns Hopkins School Of Medicine ,Doudna Lab ,Vertex Pharmaceuticals ,Broad Institute ,Pfizer ,University Of California ,Benjamin Oake Scribe Therapeutics ,Big Pharma ,Nobel Prize ,David Savage ,Crispr Therapeutics ,Johns Hopkins School ,Oake Scribe ,Avoro Ventures ,Entrepreneurial Fellowship ,Scribe Therapeutics ,Svetlana Lucas ,Johns Hopkin ,Startup Wants To Deanonymize ,Privacy Advocates Are , ,